Phase 1b Study To Assess The Safety, Tolerability, And Clinical Activity Of Gedatolisib In Combination With Palbociclib And Either Letrozole Or Fulvestrant In Women With Metastatic Or Locally Advanced/Recurrent Breast Cancer (MBC)
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Fulvestrant (Primary) ; Gedatolisib (Primary) ; Letrozole (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 17 Aug 2017 Planned End Date changed from 1 Nov 2019 to 24 Nov 2019.
- 17 Aug 2017 Planned primary completion date changed from 1 Nov 2019 to 24 Nov 2019.
- 24 Jul 2017 Planned End Date changed from 25 Sep 2019 to 1 Nov 2019.